Anaïs Mungo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anaïs Mungo has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Matthieu Hein
Faculté de Médecine, Université Libre de Bruxelles (ULB), 1070 Brussels, Belgium
7 shared publications - Gwenolé Loas
Department of Psychiatry, Hôpital Erasme, Université Libre de Bruxelles (ULB), 1070 Brussels, Belgium
4 shared publications Gwenolé Loas
Univ Libre Bruxelles, ULB, Dept Psychiat & Sleep Lab, Erasme Hosp, Route Lennik 808, B-1070 Anderlecht, Belgium
2 shared publicationsJean-Pol Lanquart
Erasme Hospital, Department of Psychiatry and Sleep Laboratory, Université libre de Bruxelles, ULB - Anderlecht - Bruxelles - Belgium
2 shared publications- François-Xavier Dekeuleneer
Service de Psychiatrie, Laboratoire de recherches psychiatriques (ULB 266), Université Libre de Bruxelles, ULB, hôpital Erasme, 1070 Bruxelles, Belgique
1 shared publication - Gwenolé Loas
Department of Psychiatry and Sleep Laboratory, Erasme Hospital, Université Libre de Bruxelles—ULB, 1070 Brussels, Belgium
1 shared publication
Latest Publications
- Open Access
Major Depressive Disorder, Inflammation, and Nutrition: A Tricky Pattern?
Major depressive disorder (MDD) is a psychiatric disease associated with inflammation. The Western diet (WD) is a high-fat, high-sugar diet also associated with inflammation. We aimed to show whether the diet of MDD patients was a WD and could act as a risk factor in this context. We conducted a transversal study of MDD patients and controls (CTRLs) without comorbidities. We performed blood analyses including C-reactive protein (CRP), a diet anamnesis, and an advanced glycation end-product assessment. We found that 34.37% of MDD patients had a CRP level above 3 to 10 mg/L, which remained higher than CTRLs after adjustments (sex, BMI, age, smoking status). The MDD patients had an excess of sugar and saturated and trans fatty acids; a deficiency in n-3 polyunsaturated fatty acid, monounsaturated acid, dietary fibers, and antioxidants; a high glycemic load; and aggravating nutritional factors when compared to the CTRLs. We found correlations between nutritional factors and CRP in univariate/multivariate analysis models. Thus, MDD patients showed an elevated CRP level and a WD pattern that could contribute to sustaining an inflammatory state. Further studies are required to confirm this, but the results highlighted the importance of nutrition in the context of MDD.
Open AccessMajor Depressive Disorder, Inflammation, and Nutrition: A Tricky Pattern?
Major depressive disorder (MDD) is a psychiatric disease associated with inflammation. The Western diet (WD) is a high-fat, high-sugar diet also associated with inflammation. We aimed to show whether the diet of MDD patients was a WD and could act as a risk factor in this context. We conducted a transversal study of MDD patients and controls (CTRLs) without comorbidities. We performed blood analyses including C-reactive protein (CRP), a diet anamnesis, and an advanced glycation end-product assessment. We found that 34.37% of MDD patients had a CRP level above 3 to 10 mg/L, which remained higher than CTRLs after adjustments (sex, BMI, age, smoking status). The MDD patients had an excess of sugar and saturated and trans fatty acids; a deficiency in n-3 polyunsaturated fatty acid, monounsaturated acid, dietary fibers, and antioxidants; a high glycemic load; and aggravating nutritional factors when compared to the CTRLs. We found correlations between nutritional factors and CRP in univariate/multivariate analysis models. Thus, MDD patients showed an elevated CRP level and a WD pattern that could contribute to sustaining an inflammatory state. Further studies are required to confirm this, but the results highlighted the importance of nutrition in the context of MDD.
- 26 May 2022
- Published by Elsevier in Psychiatry Research
- Vol. 314, 114650
Risk of relapse within 6 months associated with borderline personality disorder in major depressed individuals treated with electroconvulsive therapy
- 26 May 2022
- Published by Elsevier in Psychiatry Research
- Vol. 314, 114650
Risk of relapse within 6 months associated with borderline personality disorder in major depressed individuals treated with electroconvulsive therapy
- 1 April 2022
- Published by Elsevier in L'Encéphale
- Vol. 48 (2) , 171-178
La dépression majeure à caractéristique atypique comme facteur de risque du syndrome d’apnées obstructives du sommeil chez le jeune adulte
- 1 April 2022
- Published by Elsevier in L'Encéphale
- Vol. 48 (2) , 171-178
La dépression majeure à caractéristique atypique comme facteur de risque du syndrome d’apnées obstructives du sommeil chez le jeune adulte
- Open Access
- 1 March 2022
- Published by Georg Thieme Verlag KG in Sleep Science
- Vol. 15 (S 01) , 184-194
Cardiovascular risk associated with co-morbid insomnia and sleep apnoea (COMISA) in type 2 diabetics
Objective In the general population, co-morbid insomnia and sleep apnoea (COMISA) is associated with higher risk of cardiovascular diseases (CVD). However, despite a high prevalence of COMISA in type 2 diabetics, no study has investigated its potential implication in the negative cardiovascular outcome of this particular subpopulation. The aim of this study was therefore to examine the risk of CVD associated with COMISA in type 2 diabetics. Methods Data from 471 type 2 diabetics recruited from the clinical database of the Erasme Hospital sleep laboratory were analysed. Only type 2 diabetics with SCORE index ≥5% were included in the group at high risk of CVD. Logistic regression analyses were conducted to examine the risk of CVD associated with COMISA in type 2 diabetics. Results A high risk of CVD was present in 32.9% of type 2 diabetics. After adjustment for the main confounding factors associated with cardiovascular risk, multivariate logistic regression analysis revealed that unlike obstructive sleep apnoea syndrome or insomnia alone, only COMISA was associated with higher risk of CVD in type 2 diabetics. Discussion In our study, we have demonstrated that unlike its components alone, only COMISA was associated with higher risk of CVD in type 2 diabetics, which highlights the importance of the central role played by the negative synergistic effect of COMISA on the cardiovascular outcome in this particular subpopulation. Thus, given these elements, more systematic research and adequate therapeutic management of COMISA seem to be necessary to allow better cardiovascular prevention in type 2 diabetics.
- 1 March 2022
- Published by Georg Thieme Verlag KG in Sleep Science
- Vol. 15 (S 01) , 184-194
Open AccessCardiovascular risk associated with co-morbid insomnia and sleep apnoea (COMISA) in type 2 diabetics
Objective In the general population, co-morbid insomnia and sleep apnoea (COMISA) is associated with higher risk of cardiovascular diseases (CVD). However, despite a high prevalence of COMISA in type 2 diabetics, no study has investigated its potential implication in the negative cardiovascular outcome of this particular subpopulation. The aim of this study was therefore to examine the risk of CVD associated with COMISA in type 2 diabetics. Methods Data from 471 type 2 diabetics recruited from the clinical database of the Erasme Hospital sleep laboratory were analysed. Only type 2 diabetics with SCORE index ≥5% were included in the group at high risk of CVD. Logistic regression analyses were conducted to examine the risk of CVD associated with COMISA in type 2 diabetics. Results A high risk of CVD was present in 32.9% of type 2 diabetics. After adjustment for the main confounding factors associated with cardiovascular risk, multivariate logistic regression analysis revealed that unlike obstructive sleep apnoea syndrome or insomnia alone, only COMISA was associated with higher risk of CVD in type 2 diabetics. Discussion In our study, we have demonstrated that unlike its components alone, only COMISA was associated with higher risk of CVD in type 2 diabetics, which highlights the importance of the central role played by the negative synergistic effect of COMISA on the cardiovascular outcome in this particular subpopulation. Thus, given these elements, more systematic research and adequate therapeutic management of COMISA seem to be necessary to allow better cardiovascular prevention in type 2 diabetics.
- 24 February 2022
- Published by Elsevier in L'Encéphale
- Vol. 48 (4) , 455-461
L’efficacité de l’eskétamine dans le trouble dépressif majeur résistant : une revue systématique de la littérature
- 24 February 2022
- Published by Elsevier in L'Encéphale
- Vol. 48 (4) , 455-461
L’efficacité de l’eskétamine dans le trouble dépressif majeur résistant : une revue systématique de la littérature
- 1 March 2021
- Published by Elsevier in Médecine du Sommeil
- Vol. 18 (1) , 32-33
La dépression majeure à caractéristique atypique comme facteur de risque du syndrome d’apnées obstructives du sommeil chez le jeune adulte
- 1 March 2021
- Published by Elsevier in Médecine du Sommeil
- Vol. 18 (1) , 32-33
La dépression majeure à caractéristique atypique comme facteur de risque du syndrome d’apnées obstructives du sommeil chez le jeune adulte
- 30 January 2021
- Published by Elsevier in Annales Médico-psychologiques, revue psychiatrique
- Vol. 179 (6) , 492-497
Traduction et étude de validation de la version française de l’échelle « Specific Loss of Interest and Pleasure Scale, SLIPS » (Échelle de Perte Spécifique de l’Intérêt et du Plaisir, EPSIP)
- 30 January 2021
- Published by Elsevier in Annales Médico-psychologiques, revue psychiatrique
- Vol. 179 (6) , 492-497
Traduction et étude de validation de la version française de l’échelle « Specific Loss of Interest and Pleasure Scale, SLIPS » (Échelle de Perte Spécifique de l’Intérêt et du Plaisir, EPSIP)
- 28 September 2020
- Published by Springer Nature in Psychiatric Quarterly
- Vol. 91 (4) , 1333-1362
Impulsivity and its Therapeutic Management in Borderline Personality Disorder: a Systematic Review
No treatment has been approved and recognized as effective in borderline personality disorder (BPD). Impulsivity is a key dimension because it is a predictor of remission but also suicide. The purpose of this review is to establish an inventory on the management of impulsivity in BPD and determine the effective treatments. A systematic review on the PubMed and Ovid databases was conducted up to September 2019 to December 2019 using the PRISMA guidelines. The inclusion criteria were: studies with patients with borderline personality disorder, were published between 1989 and 2019, used English-language and evaluated impulsivity before and after treatment. 41 articles selected were included for pharmacological treatment. 24 articles were found for psychotherapeutic management and one randomized study of transcranial magnetic stimulation. Based on this review, we must focus on psychotherapy in BPD, particularly the schema therapy, dialectical behavioral therapy, psychoeducation, system training of emotional predictability and problem solving and psychotherapy using mentalisation. The use of neuroleptics and mood stabilizers appears to be more effective than antidepressants. Another approach, such as transcranial magnetic stimulation, may prove useful in the near future if this technique is studied further.
- 28 September 2020
- Published by Springer Nature in Psychiatric Quarterly
- Vol. 91 (4) , 1333-1362
Impulsivity and its Therapeutic Management in Borderline Personality Disorder: a Systematic Review
No treatment has been approved and recognized as effective in borderline personality disorder (BPD). Impulsivity is a key dimension because it is a predictor of remission but also suicide. The purpose of this review is to establish an inventory on the management of impulsivity in BPD and determine the effective treatments. A systematic review on the PubMed and Ovid databases was conducted up to September 2019 to December 2019 using the PRISMA guidelines. The inclusion criteria were: studies with patients with borderline personality disorder, were published between 1989 and 2019, used English-language and evaluated impulsivity before and after treatment. 41 articles selected were included for pharmacological treatment. 24 articles were found for psychotherapeutic management and one randomized study of transcranial magnetic stimulation. Based on this review, we must focus on psychotherapy in BPD, particularly the schema therapy, dialectical behavioral therapy, psychoeducation, system training of emotional predictability and problem solving and psychotherapy using mentalisation. The use of neuroleptics and mood stabilizers appears to be more effective than antidepressants. Another approach, such as transcranial magnetic stimulation, may prove useful in the near future if this technique is studied further.